secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2026-10-13T12:00:11+00:00
Accession:  0001437749-26-032499
Event type: other_material
Sentiment:  neutral
Materiality: 0.68
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Mesa Laboratories approves restructuring cutting ~40 jobs, targets $9.3M annualized savings
--------------------------------------------------------------------------------

- Board approved the Restructuring Program on October 6, 2026; ~40 positions eliminated (~6% of employees), concentrated in Clinical Genomics plus corporate functions.
- Estimated pre-tax charges of $2.6M-$3.4M, including $2.3M-$3.0M employee costs; cash expenditures of $2.9M-$3.7M, mostly within 12 months.
- Savings Plan targets ~$9.3M in annualized cost reductions with ~$4.3M reinvested, for a net ~$5.0M reduction fully reflected by end of FY2028.
- Hamburg, Germany facility will be exited when its lease expires in February 2027; San Diego, California footprint also reduced.
- CEO Siddhartha Kadia said Clinical Genomics will focus on pharmacogenomics and oncology at scale, accepting lower revenue for higher gross margin; Q2 FY2027 results set for November 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774926032499/0001437749-26-032499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774926032499/mlab20261013_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer